Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focusing on the clinical development and commercialization of seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), has announced the publication of its TORREY Phase 2 study findings in the Lancet Respiratory Medicine journal. The manuscript, titled "Seralutinib in Adults with Pulmonary Arterial Hypertension (TORREY): A Randomized, Double-blind, Placebo-controlled Phase 2 Trial," presents significant advancements in PAH treatment identified through the study.

TORREY, a Phase 2 trial, was a randomized, double-blind, placebo-controlled study conducted across multiple centers and countries. It aimed to assess the efficacy and safety of Gossamer’s novel therapy, seralutinib, in PAH patients. PAH is a progressive condition leading to right heart failure and severely diminishing quality of life. The study included 86 patients randomized to receive either seralutinib or a placebo via dry powder inhaler twice daily for 24 weeks. The results showed a statistically significant improvement with seralutinib compared to placebo in the primary endpoint, which was the reduction of pulmonary vascular resistance (PVR), along with other crucial disease measures like right heart structure and function.

Following the successful completion of TORREY, seralutinib has been advanced into the ongoing global Phase 3 PROSERA Study, which aims to gain regulatory approval. PROSERA focuses on treating PAH in WHO Functional Class II and III PAH patients. More information about PROSERA can be accessed here: PROSERA Clinical Trial.

Gossamer Bio, commented, "The publication of the TORREY results in Lancet Respiratory Medicine marks a significant milestone in our continuous efforts to address the unmet medical needs of pulmonary hypertension patients. The findings detailed in the publication underpin our enthusiasm for the potential of seralutinib to enhance the lives of individuals grappling with this progressive disease."

 

Source: businesswire.com

Report Abuse